Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis
- 255 Downloads
Imbalance of T-helper-cell (TH) subsets (TH1/TH2/TH17) and regulatory T cells (Tregs) is suggested to contribute to the pathogenesis of osteoporosis. Broken TH17/Treg balance has been reported contributing to several inflammatory diseases. Although bisphosphonates are well-recognized inhibitors of osteoclastic activity, there is no serious examination of their effect on T cell subset (TH1/TH2/TH17/Treg) balances. Patients were categorized into 20 osteopenic and 20 osteoporotic patients treated with bisphosphonates for 1 year. We studied plasma levels of interleukins 4 (IL-4), IL-6, IL-10, IL-12, IL-17, IL-23, and interferon-gamma (IFN-γ), and transforming growth factor-beta (TGF-β) and their interrelations and correlation with osteoporosis treatment were evaluated. Treated osteoporotic patients have a significant reduction of plasma IL-6 (p < 0.05), IL-17 (p < 0.05), IL-23 (p < 0.05), and IFN-γ (p < 0.05), a significant increase in IL-4 (p < 0.05), IL-10 (p < 0.05), and TGF-β (p < 0.001), and comparable IL-12 levels as compared to controls. In conclusion, the significant reduction of Th17 cell cytokine cascade (IL-6, IL-17, and IL-23) and elevation of Treg cytokine cascade (IL-10 and TGF-β) might be considered as a very important observation about the effect of bisphosphonates on TH17/Treg imbalance in osteoporosis.
KeywordsTH1 TH2 TH17 Treg Cytokines Osteoporosis
Conflict of interest
The authors declare no conflict of interests.
- Giuliani N, Girasole G, PedrazzoniM Passeri G, Gatti C, Passeri M (1995) Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10:S171Google Scholar
- Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759):304–309CrossRefPubMedGoogle Scholar
- Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352CrossRefPubMedCentralPubMedGoogle Scholar
- Passeri G, Girasole G, Uljetti V, Guiliani N, Pedrazzoni M, Sartori L, Jilka RL, Manolagas SC (1994) Bisphosphonates inhibit IL-6 production by human osteoblastic cells MG-63. J Bone Miner Res 9(suppl):S230Google Scholar
- Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203(12):2673–2682CrossRefPubMedCentralPubMedGoogle Scholar
- Sato M, Nakamichi Y, Nakamura M, Sato N, Ninomiya T, Muto A, Nakamura H, Ozawa H, Iwasaki Y, Kobayashi E, Shimizu M, DeLuca HF, Takahashi N, Udagawa N (2007) New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone 40(2):293–304CrossRefPubMedGoogle Scholar